Гипотеза о возможных механизмах терапевтического действия гексанового экстракта Serenoa repens на состояние гипертрофированного мочевого пузыря в соответствии с патогенезом его дисфункции при инфравезикальной обструкции

Гипотеза о возможных механизмах терапевтического действия гексанового экстракта Serenoa repens на состояние гипертрофированного мочевого пузыря в соответствии с патогенезом его дисфункции при инфравезикальной обструкции

Автор: Сивков А.В., Кирпатовский В.И.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Экспериментальная урология

Статья в выпуске: 2 т.16, 2023 года.

Бесплатный доступ

Введение. Традиционно считают, что терапевтическое действие гексанового экстракта Serenoa repens (HSRE) у пациентов с доброкачественной гиперплазией предстательной железы реализуется за счет его влияния на клетки предстательной железы (ПЖ). Однако в литературе имеются данные о возможном влиянии HSRE не только на ПЖ, но и непосредственно на мочевой пузырь. В данной работе обобщены эти данные и рассмотрены возможные клеточные механизмы действия HSRE на мочевой пузырь в условиях развития инфравезикальной обструкции (ИВО). Материалы и методы. Проанализированы данные литературы из баз PubMed и eLibrary.ru за 25-летний период, связанные с изучением патогенеза дисфункции мочевого пузыря при развитии ИВО, клеточных и молекулярных механизмов, посредством которых реализуются патологические и адаптационно-приспособительные процессы в клетках мочевого пузыря, а также влияние на эти процессы HSRE. Результаты. Высказана гипотеза о плейотропном влиянии HSRE на разные звенья патогенеза дисфункции мочевого пузыря, вызванной ИВО, основными из которых являются антиоксидантный и противовоспалительный эффекты компонентов HSRE, а также регулирующее действие на факторы роста и пролиферации клеток, как и факторы транскрипции. Все это уменьшает цитотоксический эффект оксидантного стресса на клетки мочевого пузыря развивающегося при ИВО, способствуя более активной пролиферации гладкомышечных клеток детрузора. Следствием комплексного действия является поддержание сократительной функции мочевого пузыря в состоянии адаптации к повышенной нагрузке вследствие ИВО. Заключение. Изложенная гипотеза о прямом действии HSRE на гипертрофированный мочевой пузырь и возможных механизмах реализации его терапевтического действия, основана на понимании общебиологических механизмов и позволяет как лучше объяснить результаты предшествующих клинических исследований, так и оценить перспективы расширения области дальнейшего применения препарата.

Еще

Мочевой пузырь, инфравезикальная обструкция, патогенез дисфункции мочевого пузыря, serenoa repens, оксидантный стресс

Короткий адрес: https://sciup.org/142239010

IDR: 142239010   |   DOI: 10.29188/2222-8543-2023-16-2-16-30

Список литературы Гипотеза о возможных механизмах терапевтического действия гексанового экстракта Serenoa repens на состояние гипертрофированного мочевого пузыря в соответствии с патогенезом его дисфункции при инфравезикальной обструкции

  • Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms-a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54(5-6):273-9. https://doi.org/10.1016/0960-0760(95)00134-l.
  • Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, et al. Inhibition of androgen metabolism and binding by a liposterolic extract of «Seenoa repens B» in human foreskin fibroblasts. J Steroid Biochem 1984;20(1):515-9. https://doi.org/10.1016/0022-4731(84)90264-4.
  • Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998;33(3):340-7. https://doi.org/10.1159/000019570.
  • Habib FK. Serenoa repens: The scientific basis for the treatment of benign prostatic hyperplasia. Eur Urol Suppl 2009;8(13):887-93. https://doi.org/10.1016/j.eursup.2009.11.005.
  • Сивков А.В. Кирпатовский В.И. Экстракты Serenoa Repens в лечении расстройств мочеиспускания у больных ДГПЖ: дискуссия об эффективности и комплексном механизме действия. Экспериментальная и клиническая урология 2020;(4):96-105. [Sivkov A.V., Kirpatovskiy V.I. Serenoa Repens in the treatment of voiding dysfunction in patients with BPH: discussion of effectiveness and complex mechanism of action. Eksperimentalnaya i Klinicheskaya urologiya = Experimental and Clinical Urology 2020;(4):96-105. (In Russian)]. https://doi.org/10.29188/2222-8543-2020-13-4-96-104.
  • Сивков А.В., Кирпатовский В.И., Ефремов Г.Д., Голованов С.А., Дрожжева В.В. Влияние гексанового экстракта Serenoa repens на функцию мочевого пузыря при частичной инфравезикальной обструкции. Экспериментальная и клиническая урология 2023;16(1):18-28. [Sivkov A.V., Kirpatovskiy V.I., Efremov G.D., Golovanov S.A., Drozzheva. V.V. The effect of the hexanic lipidosterolic extract of Serenoa repens on the bladder function in partial bladder outlet obstruction. Eksperimentalnaya i Klinicheskaya urologiya = Experimental and Clinical Urology 2023;16(1):18-28. (In Russian)]. https://doi.org/10.29188/2222-8543-2023-16-1-18-28.
  • Lluel P, Duquenne C, Martin D. Experimental bladder instability following bladder outlet obstruction in the female rat. J Urol 1998;160(6 Pt 1):2253-7. https://doi.org/10.1097/00005392-199812010-00095.
  • Komninos C, Mitsogiannis I. Obstruction-induced alterations within the urinary bladder and their role in the pathophysiology of lower urinary tract symptomatology. Can Urol Assoc J 2014;8(7–8):524-30. https://doi.org/10.5489/cuaj.1636.
  • Кирпатовский В.И. Патогенетические механизмы развития доброкачественной гиперплазии предстательной железы и сопутствующих расстройств моче- испускания. Библиотека врача-уролога, Обнинск — Москва, 2021, 84 c. [Kirpatovskiy V.I. Pathogenetic mechanisms of development of benign prostatic hyperplasia and concomitant urination disorders. Library of a urologist, Obninsk- Moscow, 2021, 84 p. (In Russian)].
  • Levin R, Chichester P, Levin S, Buttyan R. Role of angiogenesis in bladder response to partial outlet obstruction. Scand J Urol Nephrol Suppl 2004;(215):37–47. https://doi.org/10.1080/03008880410015156.
  • Collado A, Batista E, Gelabert-Mas A, Corominas JM, Arano P, Villavicencio H. Detrusor quantitative morphometry in obstructed males and controls. J Urol 2006;176(6 Pt 1):2722-8. https://doi.org/10.1016/j.juro.2006.07.131.
  • Levin RM, English M, Barretto M, Dubuc M, O'Connor L, Leggett R, et al. Normal detrusor is more sensitive than hypertrophied detrusor to in vitro ischemia followed by re-oxygenation. Neurourol Urodyn 2000;19(6):701-12. https://doi.org/10.1002/1520-6777(2000)19:6<701::aid-nau8-3.0.co;2-w.
  • Michishita M, Yano K, Kasahara K, Tomita K, Matsuzaki O. Increased expression of 5-HT(2A) and 5-HT(2B) receptors in detrusor muscle after partial bladder outlet obstruction in rats. Biomed Res 2015;36(3):187-94. https://doi.org/10.2220/biomedres.36.187.
  • Zderic SA, Wein A, Rohrman D, Gong CL, Nigro D, Haugaard N, Levin R. Mechanisms of bladder smooth-muscle hypertrophy and decompensation: lessons from normal development and the response to outlet obstruction. World J Urol 1998;16(5):350-8. https://doi.org/10.1007/s003450050079.
  • Saito M, Wein AJ, Levin RM. Effect of partial outlet obstruction on contractility: comparison between severe and mild obstruction. Neurourol Urodyn 1993;12(6):573-83. https://doi.org/10.1002/nau.1930120610.
  • Gosling JA, Kung LS, Dixon JS, Horan P, Whitbeck C, Levin RM. Correlation between the structure and function of the rabbit urinary bladder following partial outlet obstruction. J Urol 2000;163(4):1349-56.
  • Fusco F, Creta M, De Nunzio C, Iacovelli V, Mangiapia F, Li Marzi V, et al. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urology 2018;18(1):15. https://doi.org/10.1186/s12894-018-0329-4.
  • Dixon JS, Gilpin CJ, Gilpin SA, Gosling JA, Brading AF, Speakman MJ. Sequential morphological changes in the pig detrusor in response to chronic partial urethral obstruction. Br J Urol 1989;64(4):385-90. https://doi.org/10.1111/j.1464410x.1989.tb06048.x.
  • Seki N, Karim OM, Mostwin JL. Changes in electrical properties of guinea pig smooth muscle membrane by experimental bladder outflow obstruction. Am J Physiol 1992;262(5 Pt 2):F885-91. https://doi.org/10.1152/ajprenal.1992.262.5.F885.
  • Schroder A, Uvelius B, Newgreen D, Andersson K-E. Bladder overactivity in mice after 1 week of outlet obstruction. Mainly afferent dysfunction? J Urol 2003;170(3):1017-21. https://doi.org/10.1097/01.ju.0000070926.39442.4c.
  • Malmgren A. Bladder instability and abnormal micturition patterns in rats with infravesical outflow obstruction. Neurourol Urodyn 1987;6(5):371-80.
  • Levin RM, Haugaard N, O’Connor L, Buttyan R, Das A, Dixon JS, et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn 2000;19(5):609-29. https://doi.org/10.1002/1520-6777(2000)19:5<609::aid-nau7-3.0.co;2-h.
  • Francis JA, Leggett RE, Schuler C, Levin RM. Effect of hydrogen peroxide on contractility and citrate synthase activity of the rabbit urinary bladder in the presence and absence of resveratrol and a whole-grape suspension. Mol Cell Biochem 2014;391(1-2):233-9. https://doi.org/10.1007/s11010-014-2007-5.
  • Liu C, Xu H, Fu S, Chen Y, Chen Q, Cai Z, et al. Sulforaphane ameliorates bladder dysfunction through activation of the Nrf2–ARE pathway in a rat model of partial bladder outlet obstruction. Oxid Med Cell Longev 2016;2016:7598294. https://doi.org/10.1155/2016/7598294.
  • Yuan X, Wu S, Lin T, He D, Li X, Liu S, et al. Role of nitric oxide synthase in bladder pathologic remodeling and dysfunction resulting from partial outlet obstruction. Urology 2011;77(4):1008.e1-8. https://doi.org/10.1016/j.urology.2010.11.018.
  • Callaghan CM, Schuler C, Leggett RE, Levin RM. Effect of severity and duration of bladder outlet obstruction on catalase and superoxide dismutase activity. Int J Urol 2013;20(11):1130-5. https://doi.org/10.1111/iju.12115.
  • Sezginer EK, Yilmaz-Oral D, Lokman U, Nebioglu S, Aktan F, Gur S. Effects of varying degrees of partial bladder outlet obstruction on urinary bladder function of rats: A novel link to inflammation, oxidative stress and hypoxia. Low Urin Tract Symptoms 2019;11(2):O193-O201. https://doi.org/10.1111/luts.12211.
  • de Jongh R, Haenen GR, van Koeveringe GA, Dambros M, van Kerrebroeck PE. Lipid peroxidation product 4-hydroxynonenal contributes to bladder smooth muscle damage. Urology 2008;71(5):974-8. https://doi.org/10.1016/j.urology.2007.11.014.
  • de Jongh R, Haenen GR, van Koeveringe GA, Dambros M, De Mey JG, van Kerrebroeck PE. Oxidative stress reduces the muscarinic receptor function in the urinary bladder. Neurourol Urodyn 2007;26(2):302-8. https://doi.org/10.1002/nau.20298.
  • Levin RM, Levin SS, Zhao Y, Buttyan R. Cellular and molecular aspects of bladder hypertrophy. Eur Urol 1997;32 Suppl 1:15-21.
  • Nomiya M, Andersson KE, Yamaguchi O. Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Int J Urol 2015;22(1):40-6. https://doi.org/10.1111/iju.12652.
  • Barakat AZ, Hamed AR, Bassuiny RI, Abdel-Aty AM, Mohamed SA. Date palm and saw palmetto seeds functional properties: Antioxidant, anti-inflammatory and antimicrobial activities. J Food Meas Charact 2020;(14):1064-72. https://doi.org/10.1007/s11694-019-00356-5.
  • Colado-Velázquez J-III, Mailloux-Salinas P. Medina-Contreras JML, Cruz-Robles D., Bravo G. Effect of Serenoa repens on oxidative stress, inflammatory and growth factors in obese wistar rats with benign prostatic hyperplasia. Phytother Res 2015;29(10):1525-31. https://doi.org/10.1002/ptr.5406.
  • Hughes FM Jr, Turner DP, Purves JT. The Potential repertoire of the innate immune system in the bladder: expression of pattern recognition receptors in the rat bladder and a rat urothelial cell line (MYP3 cells). Int Urol Nephrol 2015;47(12):1953- 64. https://doi.org/10.1007/s11255-015-1126-6.2015.
  • Hughes FM Jr, Vivar NP, Kennis JG, Pratt-Thomas JD, Lowe DW, Shaner BE, et al. Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation. Am J Physiol Renal Physiol 2014;306(3):F299-308. https://doi.org/10.1152/ajprenal.00297.2013.
  • Kanno Y, Mitsui T, Kitta T, Moriya K, Tsukiyama T, Hatakeyama S, et al. The inflammatory cytokine IL-1β is involved in bladder remodeling after bladder outlet obstruction in mice. Neurourol Urodyn 2016;35(3):377-81. https://doi.org/10.1002/nau.22721.
  • Metcalfe PD, Wang J, Jiao H, Huang Y, Hori K, Moore RB, et al. Bladder outlet obstruction: progression from inflammation to fibrosis. BJU Int 2010;106(11):1686-94. https://doi.org/10.1111/j.1464-410X.2010.09445.x.
  • Oka M, Fukui T, Ueda M, Tagaya M, Oyama T, Tanaka M. Suppression of bladder oxidative stress and inflammation by a phytotherapeutic agent in a rat model of partial bladder outlet obstruction. J Urol 2009;182(1):382-90. https://doi.org/10.1016/j.juro.2009.02.104.
  • Deveaud CM, Macarak EJ, Kucich U, Ewalt DH, Abrams WR, Howard PS. Molecular analysis of collagens in bladder fibrosis. J Urol 1998;160(4):1518-27.
  • Jock M, Leggett RE, Schuler C, Callaghan C, Levin RM. Effect of partial bladder outlet obstruction and reversal on rabbit bladder physiology and biochemistry: duration of recovery period and severity of function. BJU Int 2014;114(6):946-54. https://doi.org/10.1111/bju.12687.
  • Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López Farré A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double-blind pilot clinical assay. Eur Urol 2003;44(5):549-55. https://doi.org/10.1016/s0302-2838(03)00368-3.
  • Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003;56(3):171-82. https://doi.org/10.1002/pros.10238.
  • Liu L, Li Q, Han P, Li X, Zeng H, Zhu Y, Wei Q. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology 2009;74(2):340-4. https://doi.org/10.1016/j.urology.2009.02.064.
  • Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial. Am J Epidemiol 2010;171(5):571-82. https://doi.org/10.1093/aje/kwp406.
  • Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007;51(2):524-33. https://doi.org/10.1016/j.eururo.2006.07.016.
  • Sirab N, Robert G, Fasolo V, Descazeaud A, Vacherot F, de la Taille A, Terry S. Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci 2013;14(7):14301-20. https://doi.org/10.3390/ijms140714301.
  • Latil A, Petrissans M-T, Rouquet J, Robert G, de la Taille A. Effects of Hexanic extract of Serenoa repens (Permixon 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 2015;75(16):1857-67. https://doi.org/10.1002/pros.23059.
  • Разумов С.В., Медведев А.А., Чирун Н.В., Сивков А.В., Ощепков В.Н, Синюхин В.Н. Роль цитокинов в диагностике хронического простатита. Урология 2003;(6):25-28. [Razumov S.V., Medvedev A.A., Chirun N.V., Sivkov A.V., Oshepkov V.N., Sinyukhin V.H. Role of cytokines in diagnosis of chronic prostatitis. Urologiya = Urologiia 2003;(6):25-28. (In Russian)].
  • Grieb G, Merk M, Bernhagen J, Bucala R. Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect 2010;23(4):257-64. https://doi.org/10.1358/dnp.2010.23.4.1453629.
  • Greven D, Leng L, Bucala R. Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Targets 2010;14(3):253-64. https://doi.org/10.1517/14728220903551304.
  • Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007;13(5):587-96. https://doi.org/10.1038/nm1567.
  • Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002;4(4):449-60. https://doi.org/10.1016/s1286-4579(02)01560-5.
  • Vera P.L., Meyer-Siegler K.L. Anatomical location of macrophage migration inhibitory factor in urogenital tissues, peripheral ganglia and lumbosacral spinal cord of the rat. BMC Neurosci 2003;4:17. https://doi.org/10.1186/1471-2202-4-17.
  • Flaster H, Bernhagen J, Calandra T, Bucala R. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007;21(6):1267-80. https://doi.org/10.1210/me.2007-0065.
  • Ma F, Kouzoukas DE, Meyer-Siegler KL, Hunt DE, Leng L, Bucala R, et al. MIF mediates bladder pain, not inflammation, in cyclophosphamide cystitis. Cytokine X 2019;1(1):100003. https://doi.org/10.1016/j.cytox.2019.100003.
  • Michishita M, Tomita K, Yano K, Kasahara K. Mast cell accumulation and degranulation in rat bladder with partial outlet obstruction. Adv Ther 2015;32 Suppl 1:16-28. https://doi.org/10.1007/s12325-015-0243-z.
  • Chen H, Centola M, Altschul SF, Metzger H. Characterization of gene expression in resting and activated mast cells. J Exp Med 1998;188(9):1657-68. https://doi.org/10.1084/jem.188.9.1657.
  • Meyer-Siegler KL, Ordorica RC, Vera PL. Macrophage migration inhibitory factor is upregulated in an endotoxin-induced model of bladder inflammation in rats. J Interferon Cytokine Res 2004;24(1):55-63. https://doi.org/10.1089/107999004772719918.
  • Vera PL, Iczkowski KA, Leng L, Bucala R, Meyer-Siegler KL. Macrophage migration inhibitory factor is released as a complex withalpha1-inhibitor-3 in the intraluminal fluid during bladder inflammation in the rat. J Urol 2005;174(1):338-43. https://doi.org/10.1097/01.ju.0000161606.15696.79.
  • Ningyan G, Xu Y, Hongfei S. Jingjing С, Min C. The role of macrophage migration inhibitory factor in mast cell-stimulated fibro-blast proliferation and collagen production. Plos One 2015;10(3):e0122482. https://doi.org/10.1371/journal.pone.0122482.
  • Taylor JA, Zhu Q, Irwin B, Maghaydah Y, Tsimikas J, Pilbeam C, et al. Null mutation in macrophage migration inhibitory factor prevents muscle cell loss and fibrosis in partial bladder outlet obstruction. Am J Physiol Renal Physiol 2006;291(6):F1343-53. https://doi.org/10.1152/ajprenal.00144.2006.
  • Gaber T, Schellmann S, Erekul KB, Fangradt M, Tykwinska K, Hahne M, et al. Macrophage migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4+T cell proliferation under hypoxia. J Immunol 2011;186(2):764-74. https://doi.org/10.4049/jimmunol.0903421.
  • Wheeler MA, Hausladen DA, Yoon JH, Weiss RM. Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. J Urol 2002;168(4 Pt 1):1568-73. https://doi.org/10.1016/S0022-5347(05)64522-3.
  • Wheeler MA, Yoon JH, Olsson LE, Weiss RM. Cyclooxygenase-2 protein and prostaglandin E(2) production are up-regulated in a rat bladder inflammation model. Eur J Pharmacol 2001;417(3):239-48. https://doi.org/10.1016/s0014-2999(01)00911-6.
  • Mikhailidis DP, Jeremy JY, Dandonna P. Urinary bladder prostanoids – their synthesis, function and possible role in the pathogenesis and treatment of disease. J Urol 1987;137(3):577-82. https://doi.org/10.1016/s0022-5347(17)44109-7.
  • Jeremy JY, Tsang V, Mikhailidis DP, Rogers H, Morgan RJ, Dandonna P. Eicosanoid synthesis by human urinary bladder mucosa: Pathological implications. Br J Urol 1987;59(1):36-9. https://doi.org/10.1111/j.1464-410x.1987.tb04575.x.
  • Leslie CA, Pavlakis AJ, Wheeler JS, Siroky MB, Krane RJ. Release of arachidonate cascade products by the rabbit urinary bladder: Neurophysiological significance. J Urol 1984;132(2):376-9. https://doi.org/10.1016/s0022-5347(17)49631-5.
  • Zushi SY, Shinomura T, Kiyohara T, Minami T, Sugimashi M, Higashimoto S, et al. The role of prostaglandins in epithelial restitution stimulated by growth factors. Am J Physiol 1996;270(5 Pt 1):G757-62. https://doi.org/10.1152/ajpgi.1996.270.5.G757.
  • Gilmore NJ, Vane JR. Hormones released into the circulation when the urinary bladder of the anesthetized dog is distended. Clin Sci 1971;41(1):69-83. https://doi.org/10.1042/cs0410069.
  • Jeremy JY, Mikhailidis DP, Dandona P. The rat urinary bladder produces prostacyclin as well as other prostaglandins. Prostaglandins Leukot Med 1984;16(2):235-48. https://doi.org/10.1016/0262-1746(84)90074-x.
  • Khan MA, Thompson CS, Mumtaz FH, Jeremy JY, Morgan RJ, Mikhailidis DP. Role of prostaglandins in the urinary bladder: an update. Prostaglandins Leukot Fatty Acids 1998;59(6):415-22. https://doi.org/10.1016/s0952-3278(98)90104-1.
  • Park JM, Yang T, Arend LJ, Smart AM, Schnermann JB, Briggs JP. Cyclooxygenase- 2 is expressed in bladder during fetal development and stimulated by outlet obstruction. Am J Physiol 1997;273(4):F538-44. https://doi.org/10.1152/ajprenal.1997.273.4.F538.
  • Park JM, Yang T, Arend LJ, Schnermann JB, Peters CA, Freeman MR, et al. Obstruction stimulates COX-2 expression in bladder smooth muscle cells via increased mechanical stretch. Am J Physiol 1999;276(1):F129-36. https://doi.org/10.1152/ajprenal.1999.276.1.F129.
  • Hass MA, Leonova E, Levin RM. Fatty acid profiles in normal and obstructed rabbit bladder smooth muscle and mucosa. Neurourol Urodynam 1999;18(6):697-711. https://doi.org/10.1002/(sici)1520-6777(1999)18:6<697::aid-nau20-3.0.co;2-m.
  • Сергеева М.Г., Варфоломеева А.Т. Каскад арахидоновой кислоты. М., Народное образование. 2005. 277 с. [Sergeeva. M.G., Varfolomeeva A.T. Arachidonic acid cascade. M., Narodnoe obrazovanie. 2005. 277 p. (In Russian)].
  • Ishizuka O, Mattiasson A, Andersson K.-E. Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins? J Urol 1995;153(6):2034-8. https://doi.org/10.1016/s0022-5347(01)67397-x.
  • Schussler B. Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. A urodynamic study. Urol Res 1990;18(5):349-52. https://doi.org/10.1007/BF00300786.
  • Schroder A, Newgreen D, Andersson K-E. Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and EP1 receptor knockout mice. J Urol 2004;172(3):1166-70. https://doi.org/10.1097/01.ju.0000134186.58854.2c.
  • Maggi CA, Giuliani S, Conte B, Furio M, Santicioli P, Meli P, et al. Prostanoids modulate reflex micturition by acting through capsaicin-sensitive afferents. Eur J Pharmacol 1988;145(2):105-12. https://doi.org/10.1016/0014-2999(88)90221-x.
  • Tucci P, Bartocci C, Bolle P. Cyclo-oxygenase – and capsaicin-sensitive afferent fibres affect beta-adrenoceptor evoked response in the rat urinary bladder. Pharmacology 2002;64(2):57-62. https://doi.org/10.1159/000056151.
  • Ragab A, Ragab-Thomas JMF, Delhon A, Tisne-Versailles J, Gassama-Diagne A, Fauvel J. et al. Effects of Permixon (Sereprostat in Spain) on phospholipase A2 activity and on arachidonic acid metabolism in cultured prostatic cells. In: Di Silverio F., Steg A. editors. New trends in bladder cancer chemotherapy – New trends in BPH etiopathogenesis. Proceedings of the International Workshop in Urology; 1987;22-25; Cannes. Rome; Acta medica, 1988:293-296.
  • Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997;57(3):299-304. https://doi.org/10.1016/s0952-3278(97)90548-2.
  • Overview of comments received on European Union herbal monograph on Serenoa repens (W. Bartram) Small, fructus (EMA/HMPC/280079/2013 42 p.) URL: https://www.ema.europa.eu/en/documents/herbal-comments/overview-commentsreceived- european-union-herbal-monograph-serenoa-repens-w-bartram-smallfructus_en.pdf.
  • Ekman M, Uvelius B, Albinsson S, Sward K. HIF-mediated metabolic switching in bladder outlet obstruction mitigates the relaxing effect of mitochondrial inhibition. Lab Invest 2014;94(5):557-68. https://doi.org/10.1038/labinvest.2014.48.
  • Ghafar MA, Anastasiadis AG, Olsson LE, Chichester P, Kaplan SA, Buttyan R, et al. Hypoxia and an angiogenic response in the partially obstructed rat bladder. Lab Invest 2002;82(7):903-9. https://doi.org/10.1097/01.lab.0000021135.87203.92.
  • Koritsiadis G, Stravodimos K, Koutalellis G, Agrogiannis G, Koritsiadis S, Lazaris A, et al. Immunohistochemical estimation of hypoxia in human obstructed bladder and correlation with clinical variables. BJU Int 2008;102(3):328-32. https://doi.org/10.1111/j.1464-410X.2008.07593.x.
  • Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. Hypoxia-inducible factor (HIF-1) alpha: its protein stability and biological functions. Exp Mol Med 2004;36(1):1-12. https://doi.org/10.1038/emm.2004.1.
  • Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 2000;275(35):26765-71. https://doi.org/10.1074/jbc.M003325200.
  • Keith B, Adelman DM, Simon MC. Targeted mutation of the murine arylhydrocarbon receptor nuclear translocator 2 (Arnt2) gene reveals partial redundancy with Arnt. Proc Natl Acad Sci USA 2001;98(12):6692-7. https://doi.org/10.1073/pnas.121494298.
  • Stephany HA, Strand DW, Ching CB, Tanaka ST, Milne GL, Cajaiba MM, et al. Chronic cyclic bladder over distention up-regulates hypoxia dependent pathways. J Urol 2013;190(4 Suppl):1603-9. https://doi.org/10.1016/j.juro.2013.02.026.
  • Vangeison G, Carr D, Federoff HJ, Rempe DA. The good, the bad, and the cell type-specific roles of hypoxia inducible factor-1 alpha in neurons and astrocytes. J Neurosci 2008;28(8):1988-93. https://doi.org/10.1523/JNEUROSCI.5323-07.2008.
  • Sawada N, Yao J, Hiramatsu N, Hayakawa K, Araki I, Takeda M, et al. Involvement of hypoxia-triggered endoplasmic reticulum stress in outlet obstruction-induced apoptosis in the urinary bladder. Lab Invest 2008;88(5):553-63. https://doi.org/10.1038/labinvest.2008.21.
  • Wardyn JD, Ponsford AH, Sanderson CM. Dissecting molecular cross-talk between Nrf2 and NF-kappaB response pathways. Biochem Soc Trans 2015;43(4):621-6. https://doi.org/10.1042/BST20150014.
  • Persson K, Dean-Mckinney T, Steers WD, Tuttle JB. Activation of the transcription factors nuclear factor-kappaB and activator protein-1 in bladder smooth muscle exposed to outlet obstruction and mechanical stretching. J Urol 2001;165(2):633-9. https://doi.org/10.1097/00005392-200102000-00086.
  • Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, Aggarwal BB. Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem 2003;278(26):24233-41. https://doi.org/10.1074/jbc.M212389200.
  • Sarkar FH, Li Y, Wang Z, Kong D. NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008;27(5):293-319. https://doi.org/10.1080/08830180802276179.
  • Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45(1):7-17.
  • Fan EW, Chen LJ, Cheng JT, Tong YC. Changes of urinary bladder contractility in high-fat diet-fed mice: the role of tumor necrosis factor-alpha. Int J Urol 2014;21(8):831-5. https://doi.org/10.1111/iju.12428.
  • Chen M.W., Levin R.M., Buttyan R. Peptide growth factors in normal and hypertrophied bladder. World J Urol 1995;13(6):344-8. https://doi.org/10.1007/BF00191215.
  • Santarosa R, Colombell M, Kaplan S, Monson F, Levin R, Buttyan R. Hyperplasia and apoptosis: opposing cellular processes that regulate the response of the rabbit bladder to transient outlet obstruction. Lab Invest 1994;70(4):503-10.
  • Buttyan R, Jacobs BZ, Blaivas JH, Levin RM. Early molecular response to rabbit bladder outlet obstruction. Neurourol Urodyn 1992;11(3):225-38. https://doi.org/10.1002/nau.1930110306.
  • Chen M-W, Kransnapolsky L, Levin RM, Buttyan R. An early molecular response induced by acute overdistensionof the rabbit urinary bladder. Mol Cell Biochem 1994;132(1):39-44. https://doi.org/10.1007/BF00925673.
  • Chen M-W, Wein AJ, Levin RM, Buttyan R. A genetic and cellular response to unilateral ischemia of the rabbit urinary bladder. J Urol 1996;155(2):732-7.
  • Salido EC, Lakshmanan J, Fisher DA, Shapiro LJ, Barajas L. Expression of epidermal growth factor in the rat kidney. An immunohistochemicaland in situ hybridization study. Histochemistry 1991;96(1):65-72. https://doi.org/10.1007/BF00266763.
  • Nexo E, Jorgensen PE, Hansen MR. Human epidermal growth factor – on molecular forms present in urine and blood. Regul Peptide 1992;42(1-2):75-84. https://doi.org/10.1016/0167-0115(92)90025-p.
  • Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional-cell carcinoma. Cancer Res 1990;50(8):2530-7.
  • Buttyan R, Chen MW, Monson FC, Levin RM. Molecular control of rabbit urinary hypertrophy. Biomed Pharmacother 1994;48(Suppl 1):27-34s.
  • Paubert-Braquet M, Raynaud J-P, Braquet PG, Castres HC. Permixon [lipid sterolic extract of serenoa repens (LSESr)] and some of its components inhibits b-FGF – and EGF-induced proliferation of human prostate organotypic cell lines. J Urol 1997;157(Suppl):138.
  • Steers WD, Kolbeck S, Creedon D, Turtle JB. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 1991;88(5):1709-15. https://doi.org/10.1172/JCI115488.
  • Gutierrez M, García de Boto MJ, Cantabrana B, Hidalgo A. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen Pharmacol 1996;27(1):171-6. https://doi.org/10.1016/0306-3623(95)00094-1.
  • Chua T, Eise NT, Simpson JS, Ventura S. Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens): effects on rat prostate contractility. J Ethnopharmacol 2014;152(2):283-91. https://doi.org/10.1016/j.jep.2013.12.030.
  • Goepel M, Hecker U, Krege S, Rübben H, Michel MC. Saw palmetto extracts potently and noncompetitively inhibit human α1-adrenoceptors in vitro. Prostate 1999;38(3):208-15. https://doi.org/10.1002/(sici)1097-0045(19990215)38:3<208::aid-pros5-3.0.co;2-4.
  • Oki T, Suzuki M, Nishioka Y, Yasuda A, Umegaki K, Yamada S. Effects of saw palmetto extract on micturition reflex of rats and its autonomic receptor binding activity. J Urol 2005;173(4):1395-9. https://doi.org/10.1097/01.ju.0000146273.26591.f5.
  • Suzuki M, Oki T, Maruyama S, Takagi Y, Umegaki K, Nishioka Y, et al. Pharmacological effects of Saw Palmetto Extract on urodynamic functions and automic receptors in lower urinary tract of rats. Jpn Neurogenic Bladder Soc 2005;16:191-201.
  • Arruzazabala ML, Pérez Y, Ravelo Y, Molina V, Carbajal D, Mas R, et al. Effect of oleic, lauric and myristic acids on phenylephrine-induced contractions of isolated rat vas deferens. Indian J Exp Biol 2011;49(9):684-8.
  • Suzuki M, Oki T, Sugiyama T, Umegaki K, Uchida S, Yamada S. Muscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tract. Urology 2007;69(6):1216-20. https://doi.org/10.1016/j.urology.2007.02.038.
  • Nasrin S, Masuda E, Kugaya Н, Osano A, Ito Y, Yamada S. Effects of saw palmetto extract on urodynamic parameters, bladder muscarinic and purinergic receptors and urinary cytokines in rats with cyclophosphamide-induced cystitis. Low Urin Tract Symptoms 2014;6(1):57-63. https://doi.org/10.1111/luts.12015.
  • Gutiérrez M, Hidalgo A, Cantabrana B. Spasmolytic activity of a lipidic extract from Sabal serrulata fruits: further study of the mech-anisms underlying this activity. Planta Medica 1996;62(6):507-11. https://doi.org/10.1055/s-2006-957958.
  • Drescher P, Eckert RE, Madsen PO. Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate. Prostate 1994;25(2):76-80. https://doi.org/10.1002/pros.2990250204.
  • Tamalunas A, Wendt A, Springer F, Vigodski V, Ciotkowska A, Rutz B, et al. Permixon, hexane-extracted Serenoa repens, inhibits human prostate and bladder smooth muscle contraction and exerts growth-related functions in human prostate stromal cells. Life Sci 2022;308:120931. https://doi.org/10.1016/j.lfs.2022.120931.
  • Goepel M, Dinh L, Mitchell A, Schäfers RF, Rübben H, Michel MC. Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo? Prostate 2001;46(3):226-32. https://doi.org/10.1002/1097-0045(20010215)46:3<226::aid-pros1027-3.0.co;2-r.
  • Yamada S, Kato Y. Effects of saw palmetto extract on the vanilloid receptor TRPV1. Low Urin Tract Symptoms 2022;14(2):117-121. https://doi.org/10.1111/luts.12413.
  • Yamada S, Ito Y, Morikawa K, Kagota S, Shinozuka K. Effect of saw palmetto extract on urodynamic parameters, bladder contractility and pharmacological receptors in female rats. Acad J Med Plants 2020;8(12):171-8. https://doi.org/10.15413/ajmp.2020.0135.
  • Yamada S., Shirai M., Ono K., Kageyama S. Beneficial Effects of Saw Palmetto Fruit Extract on Urinary Symptoms in Japanese Female Subjects by a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Nutrients 2022, 14, 1190. https://doi.org/10.3390/nu14061190.
  • Galvin D.J., Watson R.W., O'Neill A., Coffey R.N., Taylor C., Gillespie J.I., et al. Hypoxia inhibits human bladder smooth muscle cell proliferation: a potential mechanism of bladder dysfunction. Neurourol Urodyn 2004;23(4):342-8.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp